Cargando…
Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis
PURPOSE: The purpose of this study is to compare the different EGFR mutation status in patients with metastatic non-small cell lung cancer (NSCLC) after first-line EGFR-TKIs therapy and analyze its relationship with efficacy and prognosis. PATIENTS AND METHODS: This study retrospectively analyzed th...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423412/ https://www.ncbi.nlm.nih.gov/pubmed/34512029 http://dx.doi.org/10.2147/CMAR.S329900 |
_version_ | 1783749460308787200 |
---|---|
author | Yuan, Chengliang Jiang, Huiqin Jiang, Wei Wang, Huilin Su, Cuiyun Zhou, Shaozhang |
author_facet | Yuan, Chengliang Jiang, Huiqin Jiang, Wei Wang, Huilin Su, Cuiyun Zhou, Shaozhang |
author_sort | Yuan, Chengliang |
collection | PubMed |
description | PURPOSE: The purpose of this study is to compare the different EGFR mutation status in patients with metastatic non-small cell lung cancer (NSCLC) after first-line EGFR-TKIs therapy and analyze its relationship with efficacy and prognosis. PATIENTS AND METHODS: This study retrospectively analyzed the data of patients with metastatic NSCLC harboring EGFR mutation in the Affiliated Tumor Hospital of Guangxi Medical University from June 2016 to December 2020. Samples were collected before treatment and at the time of disease progression after first-line EGFR-TKIs therapy. Amplification refractory mutation system (ARMS) PCR and next-generation sequencing (NGS) were used to detect EGFR mutation. ORR, DCR, and PFS of different EGFR mutation groups were compared. RESULTS: The EGFR mutation rate of re-biopsy was 60.23%. The inconsistency rate of EGFR mutations in the same and different simple types was 72.22% (26/36) and 92.31% (48/52), respectively. Alterations in terms of EGFR mutations were divided into four groups: Group A: EGFR-sensitive mutation negative and T790M negative (39.77%); Group B: EGFR-sensitive mutation positive and T790M negative (18.19%); Group C: EGFR-sensitive mutation negative and T790M positive (36.36%); Group D: EGFR-sensitive mutation positive and T790M positive (5.68%). The differences between the four groups in ORR and DCR were not statistically significant (P>0.05). The median PFS of all patients was 10.65 months. PFS of Group A, B, C, and D was 12.26, 7.96, 10.55, and 13.81 months, respectively, with statistical significance (Log rank P = 0.014). CONCLUSION: EGFR mutation status in metastatic NSCLC patients receiving the first- and second-generation TKIs after disease progression show diversity. Monitoring the EGFR mutation changes is of great importance for subsequent clinical decision-making and exploring the underlying mechanisms of acquired resistance. |
format | Online Article Text |
id | pubmed-8423412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-84234122021-09-09 Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis Yuan, Chengliang Jiang, Huiqin Jiang, Wei Wang, Huilin Su, Cuiyun Zhou, Shaozhang Cancer Manag Res Original Research PURPOSE: The purpose of this study is to compare the different EGFR mutation status in patients with metastatic non-small cell lung cancer (NSCLC) after first-line EGFR-TKIs therapy and analyze its relationship with efficacy and prognosis. PATIENTS AND METHODS: This study retrospectively analyzed the data of patients with metastatic NSCLC harboring EGFR mutation in the Affiliated Tumor Hospital of Guangxi Medical University from June 2016 to December 2020. Samples were collected before treatment and at the time of disease progression after first-line EGFR-TKIs therapy. Amplification refractory mutation system (ARMS) PCR and next-generation sequencing (NGS) were used to detect EGFR mutation. ORR, DCR, and PFS of different EGFR mutation groups were compared. RESULTS: The EGFR mutation rate of re-biopsy was 60.23%. The inconsistency rate of EGFR mutations in the same and different simple types was 72.22% (26/36) and 92.31% (48/52), respectively. Alterations in terms of EGFR mutations were divided into four groups: Group A: EGFR-sensitive mutation negative and T790M negative (39.77%); Group B: EGFR-sensitive mutation positive and T790M negative (18.19%); Group C: EGFR-sensitive mutation negative and T790M positive (36.36%); Group D: EGFR-sensitive mutation positive and T790M positive (5.68%). The differences between the four groups in ORR and DCR were not statistically significant (P>0.05). The median PFS of all patients was 10.65 months. PFS of Group A, B, C, and D was 12.26, 7.96, 10.55, and 13.81 months, respectively, with statistical significance (Log rank P = 0.014). CONCLUSION: EGFR mutation status in metastatic NSCLC patients receiving the first- and second-generation TKIs after disease progression show diversity. Monitoring the EGFR mutation changes is of great importance for subsequent clinical decision-making and exploring the underlying mechanisms of acquired resistance. Dove 2021-09-03 /pmc/articles/PMC8423412/ /pubmed/34512029 http://dx.doi.org/10.2147/CMAR.S329900 Text en © 2021 Yuan et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Yuan, Chengliang Jiang, Huiqin Jiang, Wei Wang, Huilin Su, Cuiyun Zhou, Shaozhang Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis |
title | Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis |
title_full | Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis |
title_fullStr | Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis |
title_full_unstemmed | Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis |
title_short | Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis |
title_sort | comparison of different egfr gene mutation status in patients with metastatic non-small lung cancer after first-line egfr-tkis therapy and analyzing its relationship with efficacy and prognosis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423412/ https://www.ncbi.nlm.nih.gov/pubmed/34512029 http://dx.doi.org/10.2147/CMAR.S329900 |
work_keys_str_mv | AT yuanchengliang comparisonofdifferentegfrgenemutationstatusinpatientswithmetastaticnonsmalllungcancerafterfirstlineegfrtkistherapyandanalyzingitsrelationshipwithefficacyandprognosis AT jianghuiqin comparisonofdifferentegfrgenemutationstatusinpatientswithmetastaticnonsmalllungcancerafterfirstlineegfrtkistherapyandanalyzingitsrelationshipwithefficacyandprognosis AT jiangwei comparisonofdifferentegfrgenemutationstatusinpatientswithmetastaticnonsmalllungcancerafterfirstlineegfrtkistherapyandanalyzingitsrelationshipwithefficacyandprognosis AT wanghuilin comparisonofdifferentegfrgenemutationstatusinpatientswithmetastaticnonsmalllungcancerafterfirstlineegfrtkistherapyandanalyzingitsrelationshipwithefficacyandprognosis AT sucuiyun comparisonofdifferentegfrgenemutationstatusinpatientswithmetastaticnonsmalllungcancerafterfirstlineegfrtkistherapyandanalyzingitsrelationshipwithefficacyandprognosis AT zhoushaozhang comparisonofdifferentegfrgenemutationstatusinpatientswithmetastaticnonsmalllungcancerafterfirstlineegfrtkistherapyandanalyzingitsrelationshipwithefficacyandprognosis |